[an error occurred while processing this directive] | [an error occurred while processing this directive]
Progress in the application of rituximab in treating primary mediastinal B-cell lymphoma
Xu Liming,Yuan Yajing,Wang Peiguo,Wu Gang
Department of Radiation Oncology and Anesthesia,Tianjin Medical University Cancer Institute& Hospital,Key Laboratory of Cancer Prevention and Therapy,National Clinical Research Center for Cancer,Tianjin 300060,China (Xu LM,Wang PG,Yuan YJ);Cancer center,WuhanUnion Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China (Wu G)
Abstract Primary mediastinal large B-cell lymphoma (PMBCL) is morphologically similar to diffuse large B-cell lymphoma (DLBCL) and nodular sclerosis Hodgkin lymphoma. For most PMBCL patients, chemotherapy plus consolidation radiotherapy showed that the latter could improve PMBCL responsiveness and progression-free survival (PFS), and its combined use with chemotherapy demonstrated higher therapeutic efficacy. Recent clinical studies suggested that rituximab and anthracycline chemotherapy regimens could increase PMBCL treatment efficacy, reduce early treatment failure, enhance PFS and overall survival, and improve prognosis. Although rituximab combined with some high-intensity chemotherapy without radiotherapy have achieved good results, many studies still support the use of post-immunochemotherapy consolidation mediastinal radiotherapy. Based on the results of a few studies with a small sample size, patients who were assessed as complete metabolic remission by PET following high-intensity immunochemotherapy may omit consolidation radiotherapy. However, these results will need to be further confirmed by large-sample multicenter clinical trials. Consolidation radiotherapy is recommended for patients with poor prognostic factors or PET score>3.
Xu Liming,Yuan Yajing,Wang Peiguo et al. Progress in the application of rituximab in treating primary mediastinal B-cell lymphoma[J]. Chinese Journal of Radiation Oncology, 2017, 26(5): 582-587.
Xu Liming,Yuan Yajing,Wang Peiguo et al. Progress in the application of rituximab in treating primary mediastinal B-cell lymphoma[J]. Chinese Journal of Radiation Oncology, 2017, 26(5): 582-587.
[1] Lichtenstein AK,Levine A,Taylor CR,et al. Primary mediastinal lymphoma in adults[J].Am J Med,1980,68(4):509-514. [2] Harris NL,Jaffe ES,Stein H,et al. A revised European-American classification of lymphoid neoplasms:a proposal from the International Lymphoma Study Group[J].Blood,1994,84(5):1361-1392. [3] Gaulard P,Harris NL,Pileri SA,et al. Primary mediastinal (thymic) large B-cell lymphoma. In:Jaffe ES,Harris NL,Stein H,Vardiman JW,eds. World Health Organization Classification of Tumours:Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon,France:IARC Press;2008:250-251. [4] Rosenwald A,Wright G,Leroy K,et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma[J].J Exp Med,2003,198(6):851-862.DOI:10.1084/jem.20031074. [5] Gunawardana J,Chan FC,Telenius A,et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma[J].Nat Genet,2014,46(4):329-335.DOI:10.1038/ng.2900. [6] Martelli M,Ferreri AJ,Johnson P.Primary mediastinal large B-cell lymphoma[J].Crit Rev Oncol Hematol,2008,68(3):256-263.DOI:10.1016/j.critrevonc.2008.07.020. [7] Bhatt VR,Mourya R,Shrestha R,et al. Primary mediastinal large B-cell lymphoma[J].Cancer Treat Rev,2015,41(6):476-485.DOI:10.1016/j.ctrv.2015.04.006. [8] Miller TP,Dahlberg S,Cassady JR,et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin′s lymphoma[J].N Engl J Med,1998,339(1):21-26.DOI:10.1056/NEJM199807023390104. [9] Horning SJ,Weller E,Kim K,et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin′s lymphoma:Eastern Cooperative Oncology Group study 1484[J].J Clin Oncol,2004,22(15):3032-3038.DOI:10.1200/JCO.2004.06.088. [10] Miller TP,Leblanc M,Spier C,et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin’s lymphomas:Update of the Southwest Oncology Group (SWOG) randomized trial. Blood,2001,98:724A-725A. [11] Dunleavy K,Pittaluga S,Maeda LS,et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma[J].N Engl J Med,2013,368(15):1408-1416.DOI:10.1056/NEJMoa1214561. [12] Rieger M,Osterborg A,Pettengell R,et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab:results of the Mabthera International Trial Group study[J].Ann Oncol,2011,22(3):664-670.DOI:10.1093/annonc/mdq418. [13] Tai WM,Quah D,Yap SP,et al. Primary mediastinal large B-cell lymphoma:optimal therapy and prognostic factors in 41 consecutive Asian patients[J].Leuk Lymphoma,2011,52(4):604-612.DOI:10.3109/10428194.2010.550073. [14] Savage KJ,Al-Rajhi N,Voss N,et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution:the British Columbia experience[J].Ann Oncol,2006,17(1):123-130.DOI:10.1093/annonc/mdj030. [15] Zhu YJ,Huang JJ,Xia Y,et al. Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients:clinical characteristics and prognostic factors[J].Int J Hematol,2011,94(2):178-184.DOI:10.1007/s12185-011-0898-4. [16] Zinzani PL,Stefoni V,Finolezzi E,et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma:a retrospective study[J].Clin Lymphoma Myeloma,2009,9(5):381-385.DOI:10.3816/CLM.2009.n.074. [17] Ahn HK,Kim SJ,Yun J,et al. Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients[J].Int J Hematol,2010,91(3):456-463. [18] Vassilakopoulos TP,Pangalis GA,Katsigiannis A,et al. Rituximab,cyclophosphamide,doxorubicin,vincristine,and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma:the emerging standard of care[J].Oncologist,2012,17(2):239-249.DOI:10.1007/s12185-010-0536-6. [19] Aoki T,Izutsu K,Suzuki R,et al. Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma:a multicenter retrospective study in Japan[J].Haematologica,2014,99(12):1817-1825.DOI:10.3324/haematol.2014.111203. [20] Feugier P,Van Hoof A,Sebban C,et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma:a study by the Groupe d′Etude des Lymphomes de l′Adulte[J].J Clin Oncol,2005,23(18):4117-4126.DOI:10.1200/JCO.2005.09.131. [21] Pfreundschuh M,Kuhnt E,Trumper L,et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma:6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group[J].Lancet Oncol,2011,12(11):1013-1022.DOI:10.1016/S1470-2045(11)70235-2. [22] Pfreundschuh M,Ho AD,Cavallin-Stahl E,et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab:an exploratory analysis of the MabThera International Trial Group (MInT) study[J].Lancet Oncol,2008,9(5):435-444.DOI:10.1016/S1470-2045(08)70078-0. [23] Recher C,Coiffier B,Haioun C,et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B):an open-label randomised phase 3 trial[J].Lancet,2011,378(9806):1858-1867.DOI:10.1016/S0140-6736(11) 61040-4. [24] Wilson WH,Jung SH,Porcu P,et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype[J].Haematologica,2012,97(5):758-765.DOI:10.3324/haematol.2011.056531. [25] Soumerai JD,Hellmann MD,Feng Y,et al. Treatment of primary mediastinal B-cell lymphoma with rituximab,cyclophosphamide,doxorubicin,vincristine and prednisone is associated with a high rate of primary refractory disease[J].Leuk Lymphoma,2014,55(3):538-543.DOI:10.3109/10428194.2013.810738. [26] Avigdor A,Sirotkin T,Kedmi M,et al. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma[J].Ann Hematol,2014,93(8):1297-1304.DOI:10.1007/s00277-014-2043-y. [27] Zinzani PL,Broccoli A,Casadei B,et al. The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma:experience on 74 patients[J].Hematol Oncol,2015,33(4):145-150.DOI:10.1002/hon.2172. [28] Schwarzbich MA,Schoning T,Cremer M,et al. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment[J].Leuk Lymphoma,2016,57(7):1723-1726.DOI:10.3109/10428194.2015.1113274. [29] Illidge T,Specht L,Yahalom J,et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group[J].Int J Radiat Oncol Biol Phys,2014,89(1):49-58.DOI:10.1016/j.ijrobp.2014.01.006. [30] Isohashi K,Tatsumi M,Kato H,et al. Prognostic Value of FDG-PET,Based on the Revised Response Criteria,in Patients with Malignant Lymphoma:A Comparison with CT/MRI Evaluations,Based on the International Working Group/Cotswolds Meeting Criteria[J].Asia Ocean J Nucl Med Biol,2015,3(2):91-98. [31] Persky DO,Unger JM,Spier CM,et al. Phase Ⅱ study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma:Southwest Oncology Group study 0014[J].J Clin Oncol,2008,26(14):2258-2263.DOI:10.1200/JCO.2007.13.6929. [32] Zinzani PL,Martelli M,Bertini M,et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis:a retrospective multinational study on 426 previously untreated patients[J].Haematologica,2002,87(12):1258-1264. [33] Todeschini G,Secchi S,Morra E,et al. Primary mediastinal large B-cell lymphoma (PMLBCL):long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B[J].Br J Cancer,2004,90(2):372-376.DOI:10.1038/sj.bjc.6601460. [34] De Sanctis V,Finolezzi E,Osti MF,et al. MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma[J].Int J Radiat Oncol Biol Phys,2008,72(4):1154-1160.DOI:10.1016/j.ijrobp.2008.02.036. [35] Xu LM,Fang H,Wang WH,et al. Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy[J].Leuk Lymphoma,2013,54(8):1684-1690.DOI:10.3109/10428194.2012.746684. [36] Hamlin PA,Portlock CS,Straus DJ,et al. Primary mediastinal large B-cell lymphoma:optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999[J].Br J Haematol,2005,130(5):691-699.DOI:10.1111/j.1365-2141.2005.05661.x. [37] Massoud M,Koscielny S,Lapusan S,et al. Primary mediastinal large B-cell lymphomas treated with dose-intensified CHOP alone or CHOP combined with radiotherapy[J].Leuk Lymphoma,2008,49(8):1510-1515.DOI:10.1080/10428190802203788. [38] Moskowitz C,Hamlin PA,Maragulia J,et al. Sequential Dose-Dense RCHOP Followed by ICE Consolidation (MSKCC protocol 01–142) without Radiotherapy for Patients with Primary Mediastinal Large B Cell Lymphoma. ASH Annual Meet Abstr,2010,116(21):420. [39] Savage KJ,Yenson PR,Shenkier T,et al. The outcome of primary mediastinal large B cell lymphoma (PMBCL) in the R-CHOP treatment era. ASH Annual Meet Abstr,2012,120(21):303. [40] Randomized,Open-label,Two-arms,Phase Ⅲ Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma. ClinicalTrials.gov,‘‘Search for Clinical Trials,’’ 17 January 2016,<http://www.clinicaltrials.gov/>. [41] Murray L,Sethugavalar B,Robertshaw H,et al. Involved Node,Site,Field and Residual Volume Radiotherapy for Lymphoma:A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks[J].Clin Oncol (R Coll Radiol),2015,27(7):401-410.DOI:10.1016/j.clon.2015.03.005. [42] Goldschmidt N,Kleinstern G,Orevi M,et al. Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy[J].Cancer Chemother Pharmacol,2016,77(5):1053-1060.DOI:10.1007/s00280-016-3024-8. [43] Pinnix CC,Dabaja B,Ahmed MA,et al. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography[J].Int J Radiat Oncol Biol Phys,2015,92(1):113-121.DOI:10.1016/j.ijrobp.2015.02.006. [44] Filippi AR,Ciammella P,Piva C,et al. Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma[J].Int J Radiat Oncol Biol Phys,2014,89(2):370-375.DOI:10.1016/j.ijrobp.2014.01.041. [45] Mulvihill DJ,McMichael K,Goyal S,et al. Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy[J].Radiother Oncol,2014,112(2):279-283.DOI:10.1016/j.radonc.2014.06.018. [46] Paumier A,Ghalibafian M,Gilmore J,et al. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin′s lymphoma[J].Int J Radiat Oncol Biol Phys,2012,82(4):1522-1527.DOI:10.1016/j.radonc.2014.06.018. [47] Lu NN,Li YX,Wu RY,et al. Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin′s lymphoma with mediastinal involvement[J].Int J Radiat Oncol Biol Phys,2012,84(1):210-216.DOI:10.1016/j.ijrobp.2011.11.008. [48] Xu LM,Li YX,Fang H,et al. Dosimetric evaluation and treatment outcome of intensity modulated radiation therapy after doxorubicin-based chemotherapy for primary mediastinal large B-cell lymphoma[J].Int J Radiat Oncol Biol Phys,2013,85(5):1289-1295.DOI:10.1016/j.ijrobp.2012.10.037. [49] Juweid ME,Stroobants S,Hoekstra OS,et al. Use of positron emission tomography for response assessment of lymphoma:consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma[J].J Clin Oncol,2007,25(5):571-578.DOI:10.1200/JCO.2006.08.2305. [50] Vassilakopoulos TP,Pangalis GA,Chatziioannou S,et al. PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP:An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy[J].Leukemia,2016,30(1):238-242.DOI:10.1038/leu.2015.120. [51] Martelli M,Ceriani L,Zucca E,et al.[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma:results of the International Extranodal Lymphoma Study Group IELSG-26 Study[J].J Clin Oncol,2014,32(17):1769-1775.DOI:10.1200/JCO.2013.51.7524. [52] Meignan M,Gallamini A,Meignan M,et al. Report on the First International Workshop on Interim-PET-Scan in Lymphoma[J].Leuk Lymphoma,2009,50(8):1257-1260.DOI:10.1080/10428190903040048. [53] Barrington SF,Mikhaeel NG,Kostakoglu L,et al. Role of imaging in the staging and response assessment of lymphoma:consensus of the International Conference on Malignant Lymphomas Imaging Working Group[J].J Clin Oncol,2014,32(27):3048-3058.DOI:10.1200/JCO.2013.53.5229. [54] Filippi AR,Piva C,Giunta F,et al. Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy[J].Int J Radiat Oncol Biol Phys,2013,87(2):311-316.DOI:10.1016/j.ijrobp.2013.05.053. [55] Cheson BD.Role of functional imaging in the management of lymphoma[J].J Clin Oncol,2011,29(14):1844-1854.DOI:10.1200/JCO.2010.32.5225. [56] Nagle SJ,Chong EA,Chekol S,et al. The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma[J].Cancer Med,2015,4(1):7-15.DOI:10.1002/cam4.322. [57] Cheah CY,Hofman MS,Seymour JF,et al. The utility and limitations of (18) F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma:single institution experience and literature review[J].Leuk Lymphoma,2015,56(1):49-56.DOI:10.3109/10428194.2014.910656.
2017, Vol. 26 
